$3.27
0.91% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US23666P1012
Symbol
DARE
Sector
Industry

Dare Bioscience, Inc. Stock price

$3.27
-0.03 0.91% 1M
-1.15 26.05% 6M
-0.44 11.81% YTD
-0.79 19.38% 1Y
-21.93 87.02% 3Y
-6.57 66.77% 5Y
-770.72 99.58% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.03 0.91%
ISIN
US23666P1012
Symbol
DARE
Sector
Industry

Key metrics

Market capitalization $28.45m
Enterprise Value $23.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 12.29
P/S ratio (TTM) P/S ratio 15.13
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 88.13%
Revenue (TTM) Revenue $1.88m
EBIT (operating result TTM) EBIT $-23.13m
Free Cash Flow (TTM) Free Cash Flow $-8.63m
Cash position $11.23m
EPS (TTM) EPS $-0.44
P/E forward negative
P/S forward 26.35
EV/Sales forward 21.40
Short interest 0.35%
Show more

Is Dare Bioscience, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Dare Bioscience, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Dare Bioscience, Inc. forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Dare Bioscience, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Dare Bioscience, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.88 1.88
88% 88%
100%
- Direct Costs 0.05 0.05
67% 67%
3%
1.84 1.84
90% 90%
98%
- Selling and Administrative Expenses 10 10
16% 16%
544%
- Research and Development Expense 15 15
52% 52%
781%
-23 -23
45% 45%
-1,228%
- Depreciation and Amortization 0.05 0.05
67% 67%
3%
EBIT (Operating Income) EBIT -23 -23
45% 45%
-1,230%
Net Profit -3.60 -3.60
91% 91%
-191%

In millions USD.

Don't miss a Thing! We will send you all news about Dare Bioscience, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dare Bioscience, Inc. Stock News

Neutral
Seeking Alpha
about one month ago
Daré Bioscience, Inc. (NASDAQ:DARE ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO Conference Call Participants Catherine Novack - JonesTrading Brian Kemp Dolliver - Brookline Capital Markets Douglas Tsao - H.C. Wainwright Operator Welcome to the conference call hosted by Daré Bioscience...
Neutral
GlobeNewsWire
about one month ago
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3 contraceptive efficacy study recruiting across the United States; foundation grant announced yesterday will provide funding to allow Daré to expand the number of clinical sites to accelerate the developm...
Neutral
GlobeNewsWire
about 2 months ago
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 14, 2024, to review its financial results for the quarter ended September 30, 2024 and to provide a company update. The company will release its financial res...
More Dare Bioscience, Inc. News

Company Profile

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Head office United States
CEO Sabrina Johnson
Employees 26
Founded 2015
Website www.darebioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today